Bayer AG NA (BAYN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bayer AG NA (BAYN) has a cash flow conversion efficiency ratio of 0.142x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€3.69 Billion ≈ $4.31 Billion USD) by net assets (€26.06 Billion ≈ $30.47 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BAYN net asset quality score to measure how much of total assets are equity-financed.
Bayer AG NA - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Bayer AG NA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Bayer AG NA to evaluate the quality of earnings relative to operating cash generation.
Bayer AG NA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bayer AG NA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vulcan Materials Company
NYSE:VMC
|
0.064x |
|
Powszechna Kasa Oszczednosci Bank Polski SA
WAR:PKO
|
0.131x |
|
AHOLD DELHAI.ADR16 EO-25
F:AHOD
|
0.051x |
|
Commerzbank AG
F:ZZMS
|
-0.215x |
|
NTPC Limited
NSE:NTPC
|
0.253x |
|
China CSSC Holdings Ltd
SHG:600150
|
0.014x |
|
Prudential Financial Inc
NYSE:PRU
|
-0.014x |
|
WEC Energy Group Inc
NYSE:WEC
|
0.084x |
Annual Cash Flow Conversion Efficiency for Bayer AG NA (1998–2025)
The table below shows the annual cash flow conversion efficiency of Bayer AG NA from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see BAYN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €26.06 Billion ≈ $30.47 Billion |
€4.57 Billion ≈ $5.34 Billion |
0.175x | -23.72% |
| 2024-12-31 | €32.05 Billion ≈ $37.46 Billion |
€7.37 Billion ≈ $8.61 Billion |
0.230x | +48.63% |
| 2023-12-31 | €33.08 Billion ≈ $38.67 Billion |
€5.12 Billion ≈ $5.98 Billion |
0.155x | -15.10% |
| 2022-12-31 | €38.93 Billion ≈ $45.51 Billion |
€7.09 Billion ≈ $8.29 Billion |
0.182x | +18.76% |
| 2021-12-31 | €33.17 Billion ≈ $38.78 Billion |
€5.09 Billion ≈ $5.95 Billion |
0.153x | -3.93% |
| 2020-12-31 | €30.70 Billion ≈ $35.89 Billion |
€4.90 Billion ≈ $5.73 Billion |
0.160x | -7.53% |
| 2019-12-31 | €47.52 Billion ≈ $55.55 Billion |
€8.21 Billion ≈ $9.59 Billion |
0.173x | +0.68% |
| 2018-12-31 | €46.15 Billion ≈ $53.95 Billion |
€7.92 Billion ≈ $9.26 Billion |
0.172x | -22.26% |
| 2017-12-31 | €36.86 Billion ≈ $43.09 Billion |
€8.13 Billion ≈ $9.51 Billion |
0.221x | -22.56% |
| 2016-12-31 | €31.90 Billion ≈ $37.29 Billion |
€9.09 Billion ≈ $10.63 Billion |
0.285x | +5.23% |
| 2015-12-31 | €25.45 Billion ≈ $29.75 Billion |
€6.89 Billion ≈ $8.06 Billion |
0.271x | -5.77% |
| 2014-12-31 | €20.22 Billion ≈ $23.64 Billion |
€5.81 Billion ≈ $6.79 Billion |
0.287x | +15.61% |
| 2013-12-31 | €20.80 Billion ≈ $24.32 Billion |
€5.17 Billion ≈ $6.05 Billion |
0.249x | +1.84% |
| 2012-12-31 | €18.57 Billion ≈ $21.71 Billion |
€4.53 Billion ≈ $5.30 Billion |
0.244x | -7.05% |
| 2011-12-31 | €19.27 Billion ≈ $22.53 Billion |
€5.06 Billion ≈ $5.92 Billion |
0.263x | -14.06% |
| 2010-12-31 | €18.90 Billion ≈ $22.09 Billion |
€5.77 Billion ≈ $6.75 Billion |
0.306x | +7.72% |
| 2009-12-31 | €18.95 Billion ≈ $22.16 Billion |
€5.38 Billion ≈ $6.28 Billion |
0.284x | +28.45% |
| 2008-12-31 | €16.34 Billion ≈ $19.10 Billion |
€3.61 Billion ≈ $4.22 Billion |
0.221x | -13.28% |
| 2007-12-31 | €16.82 Billion ≈ $19.67 Billion |
€4.28 Billion ≈ $5.01 Billion |
0.255x | -22.14% |
| 2006-12-31 | €12.85 Billion ≈ $15.02 Billion |
€4.20 Billion ≈ $4.91 Billion |
0.327x | +1.90% |
| 2005-12-31 | €10.90 Billion ≈ $12.75 Billion |
€3.50 Billion ≈ $4.09 Billion |
0.321x | +62.15% |
| 2004-12-31 | €12.37 Billion ≈ $14.46 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.198x | -25.85% |
| 2003-12-31 | €12.31 Billion ≈ $14.40 Billion |
€3.29 Billion ≈ $3.84 Billion |
0.267x | -6.66% |
| 2002-12-31 | €15.47 Billion ≈ $18.08 Billion |
€4.42 Billion ≈ $5.17 Billion |
0.286x | +26.11% |
| 2001-12-31 | €17.05 Billion ≈ $19.93 Billion |
€3.87 Billion ≈ $4.52 Billion |
0.227x | +20.15% |
| 2000-12-31 | €16.42 Billion ≈ $19.20 Billion |
€3.10 Billion ≈ $3.62 Billion |
0.189x | -11.92% |
| 1999-12-31 | €15.18 Billion ≈ $17.75 Billion |
€3.25 Billion ≈ $3.80 Billion |
0.214x | -3.86% |
| 1998-12-31 | €12.78 Billion ≈ $14.94 Billion |
€2.85 Billion ≈ $3.33 Billion |
0.223x | -- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; speci… Read more